$TVTX News

Travere Therapeutics: Valuation Suggests A Buy

Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78

Travere Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75

Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again)

TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75

Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85

Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $68

Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $75

Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On

Travere Therapeutics (NASDAQ:TVTX) Beats Q2 Revenue Estimates on FILSPARI Sales Growth

Travere Therapeutics, Inc. (TVTX) Q2 2026 Earnings Call Transcript

Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $62

Travere Therapeutics (NASDAQ:TVTX) Earns Perfect Ratings in Breakout Setup Screen

Travere Therapeutics (NASDAQ:TVTX): High Growth Momentum Stock with Breakout Setup

Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform

Travere Therapeutics (NASDAQ:TVTX) - High Growth Momentum and Technical Breakout Setup

Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $65

Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $61